• Home
  • News

Zoetis Reports Third Quarter 2015 Results

  • Delivers 9% Operational Growth in Revenue and 31% Operational Growth in Adjusted Net Income, Excluding Foreign Exchange
  • Third Quarter 2015 Reported Revenue of $1.2 Billion Was Flat Compared to Third Quarter 2014
  • Third Quarter 2015 Reported Net Income of $189 Million, or $0.38 Per Diluted Share, Increased 14% and 15%, Respectively, Compared to Third Quarter 2014
  • Third Quarter 2015 Adjusted Net Income1 of $252 Million, or Adjusted Diluted EPS1 of $0.50, Increased 22% Compared to Third Quarter 2014
  • Updates Full Year 2015 Revenue Guidance to $4.700 - $4.750 Billion and Full Year 2015 Adjusted Diluted EPS1 Guidance to $1.70 - $1.74
  • Updates Financial Outlook for Full Year 2016 and 2017
Tuesday, November 3, 2015 7:00 am EST

Dateline:

FLORHAM PARK, N.J.

Public Company Information:

NYSE:
ZTS
"Despite some global economic challenges, the animal health industry remains resilient based on the strong fundamental drivers for improved protein production and healthier pets"

FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2015, and updated its full year 2015 guidance, as well as its financial outlook for full year 2016 and 2017.

The company reported revenue of $1.2 billion for the third quarter of 2015, which was flat compared to the third quarter of 2014. Revenue reflected an operational2 increase of 9%, excluding the impact of foreign exchange.

Net income for the third quarter of 2015 was $189 million, or $0.38 per diluted share, an increase of 14% and 15%, respectively, compared to the third quarter of 2014. Adjusted net income1 for the third quarter of 2015 was $252 million, or $0.50 per diluted share, an increase of 22% compared to the third quarter of 2014. Adjusted net income for the third quarter of 2015 excludes the net impact of $63 million, or $0.12 per diluted share, for purchase accounting adjustments, acquisition-related costs and certain significant items. On an operational basis, adjusted net income for the third quarter of 2015 increased 31% compared to the third quarter of 2014, with foreign currency having a negative impact of 9%.

EXECUTIVE COMMENTARY

“We continued to deliver strong revenue and adjusted net income growth this quarter, based on our diverse portfolio of high-quality products and our continued discipline on costs and expenses,” said Zoetis Chief Executive Officer Juan Ramón Alaix. “We generated operational growth of 9% in revenue and 31% in adjusted net income, delivering adjusted diluted EPS of 50 cents per share. This quarter’s growth was largely due to the performance of our livestock business in the U.S., the integration of Abbott Animal Health products into our business, and the growth of recent product launches, led by APOQUEL."

“Despite some global economic challenges, the animal health industry remains resilient based on the strong fundamental drivers for improved protein production and healthier pets,” said Alaix. “Our growth strategies and resources are aligned against these drivers to expand our market leadership in the industry. The recently announced acquisition of PHARMAQ, a market-leading company in aquatic health, is an example of this growth strategy and will bring us another platform and pipeline to strengthen our core livestock business.”

“The financial highlights of the quarter were once again operational revenue growth across our portfolio and cost discipline that drove significant growth in adjusted net income,” said Zoetis Chief Financial Officer Paul Herendeen. “The productivity of our R&D engine and performance in the U.S. and key emerging markets like Brazil and China give us confidence in our future prospects. With this view, we are updating our guidance for full year 2015 and our outlook for full year 2016 and 2017, while managing the expected headwinds of foreign exchange.”

QUARTERLY HIGHLIGHTS

Zoetis organizes and manages its business across two regional operating segments: the United States (U.S.) and International. Within these segments, the company delivers a diverse portfolio of products for livestock and companion animals tailored to local trends and customer needs.

In the third quarter of 2015:

  • Revenue in the U.S. segment was $632 million, an increase of 19% compared to the third quarter of 2014. Sales of companion animal products grew 27%, led by the addition of Abbott Animal Health products and the performance of key brands including APOQUEL®, as well as REVOLUTION®, CERENIA®, PROHEART® and CONVENIA®. Sales of livestock products grew 13%, driven by sales of cattle and swine products, due primarily to the timing of seasonal buying patterns. Sales of poultry products declined slightly.
  • Revenue in the International segment was $569 million, an increase of 2% on an operational basis compared to the third quarter of 2014. In companion animal, sales grew 7% operationally, primarily driven by sales of APOQUEL and the addition of Abbott products. Sales in Japan grew significantly due to the termination of a distributor agreement that resulted in a product buyback in the prior year. Competitive pressures on REVOLUTION in certain key markets partially offset growth in companion animal products. In livestock, sales were flat operationally despite revenue growth in Brazil, Australia and China. Livestock growth in Brazil was driven by cattle due to favorable market conditions and recent product launches, as well as growth in poultry. In Australia, growth was driven by increased feedlot activity in the cattle market, while an improving pork market in China drove growth across the swine portfolio. This growth was offset by our business reduction in Venezuela and lower sales in France, which were compared to higher sales in the prior year related to changes in anti-infective legislation.

Zoetis continues to drive demand and strengthen its diverse portfolio of products through lifecycle developments, strong customer relationships and access to new markets and technologies. The company is focused on improving the performance and delivery of its current product lines; expanding product indications across species; pursuing approvals in new geographies; and developing innovative medicines, treatments and solutions for emerging diseases and unmet customer needs. Some recent highlights include:

  • Yesterday, Zoetis announced an agreement to purchase PHARMAQ, the global leader in vaccines and innovation for health products in aquaculture. Acquiring PHARMAQ, the market leader in vaccines for farmed fish, strengthens Zoetis’ core livestock business, giving the company an increased presence in the fastest growing segment of the animal health industry.
  • In the third quarter, Zoetis received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Veterinary Use (CVMP), recommending the granting of a marketing authorization for SIMPARICATM, a once-monthly chewable medication for the treatment of flea, tick and mange mite infestations in dogs beginning at age eight weeks. The active substance of SIMPARICA is sarolaner, a new ectoparasiticide belonging to the isoxazoline group.
  • Zoetis strengthened its commitment to innovation in China with the opening of a new research and development center near Beijing last week. The site will serve as home to a team of scientists who will initially focus on accelerating the development of quality vaccines tailored to the strains of illnesses that affect livestock in China. In addition, Zoetis opened a new global manufacturing and supply facility in Suzhou, China, replacing its original Suzhou manufacturing facility that opened in 1995. The site will house the manufacture of pre-mix and soluble powder medicines that will help keep farm animals healthy and set a strong foundation for future growth in China.

FINANCIAL GUIDANCE

Zoetis is updating its financial guidance for full year 2015 to reflect its most recent expectations for the fourth quarter and recent changes in foreign exchange rates:

  • Revenue of between $4.700 billion to $4.750 billion
  • Reported diluted EPS of between $0.82 to $0.89 per share
  • Adjusted diluted EPS1 of between $1.70 to $1.74 per share

The company also provided updates to its long-term outlook for:

Full Year 2016

  • Revenue of $4.750 billion to $4.875 billion
  • Reported diluted EPS of between $1.50 to $1.68 per share3
  • Adjusted cost of sales1 as a percentage of revenue of approximately 33% to 34%
  • Adjusted EBIT margin1 of approximately 31%
  • Adjusted diluted EPS of $1.84 to $1.94

Full Year 2017

  • Revenue of $5.025 billion to $5.225 billion
  • Reported diluted EPS of between $2.04 to $2.22 per share3
  • Adjusted cost of sales1 as a percentage of revenue of approximately 32% to 33%
  • Adjusted EBIT margin1 of approximately 34%
  • Adjusted diluted EPS of $2.24 to $2.38

Additional guidance on other items for 2015, 2016 and 2017, such as expenses and tax rate, are included in the financial tables and will be discussed on the company's conference call this morning.

WEBCAST & CONFERENCE CALL DETAILS

Zoetis will host a webcast and conference call at 8:30 a.m. (EST) today, during which company executives will review third quarter financial results, discuss 2015 financial guidance, talk about the acquisition of PHARMAQ, and respond to questions from financial analysts. Investors and the public may access the live webcast by visiting the Zoetis website at http://www.zoetis.com/events-and-presentations. A replay of the webcast will be archived and made available on Nov. 3, 2015.

About Zoetis

Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2014, the company generated annual revenue of $4.8 billion. With approximately 10,000 employees worldwide at the beginning of 2015, Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in 120 countries. For more information, visit www.zoetis.com.

1 Adjusted net income and its components and adjusted diluted earnings per share (non-GAAP financial measures) are defined as reported net income attributable to Zoetis and reported diluted earnings per share, excluding purchase accounting adjustments, acquisition-related costs and certain significant items.

2 Operational revenue growth is defined as revenue growth excluding the impact of foreign exchange.

3 Includes preliminary estimate of purchase price allocation for PHARMAQ.

DISCLOSURE NOTICES

Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, expectations regarding products, future use of cash and dividend payments, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, including in the sections thereof captioned “Forward-Looking Information and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.

Use of Non-GAAP Financial Measures: We use non-GAAP financial measures, such as adjusted net income and adjusted diluted earnings per share, to assess and analyze our operational results and trends and to make financial and operational decisions. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this press release should not be considered alternatives to measurements required by GAAP, such as net income, operating income, and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliation of non-GAAP financial measures and GAAP financial measures are included in the tables accompanying this press release and are posted on our website at www.zoetis.com.

Internet Posting of Information: We routinely post information that may be important to investors in the 'Investors' section of our website at www.zoetis.com, on our Facebook page at http://www.facebook.com/zoetis and on Twitter @zoetis. We encourage investors and potential investors to consult our website regularly and to follow us on Facebook and Twitter for important information about us.

           
ZOETIS INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME(a)

(UNAUDITED)
(millions of dollars, except per share data)
 
Third Quarter Nine Months
2015   2014 % Change 2015   2014 % Change
Revenue $ 1,214 $ 1,210 $ 3,491 $ 3,465 1
Costs and expenses:
Cost of sales(b) 421 434 (3) 1,242 1,226 1
Selling, general and administrative expenses(b) 374 394 (5) 1,107 1,146 (3)
Research and development expenses(b) 91 93 (2) 255 272 (6)
Amortization of intangible assets(c) 15 16 (6) 45 46 (2)
Restructuring charges and certain acquisition-related costs 13 2 * 280 10 *
Interest expense 29 29 86 87 (1)
Other (income)/deductions–net (2 ) 4   *   13   (100)
Income before provision for taxes on income 273 238 15 476 665 (28)
Provision for taxes on income 83   71   17 157   204   (23)
Net income before allocation to noncontrolling interests 190 167 14 319 461 (31)
Less: Net income attributable to noncontrolling interests 1   1   2   4   (50)
Net income attributable to Zoetis $ 189   $ 166   14 $ 317   $ 457   (31)
 
Earnings per share—basic $ 0.38   $ 0.33   15 $ 0.63   $ 0.91   (31)
 
Earnings per share—diluted $ 0.38   $ 0.33   15 $ 0.63   $ 0.91   (31)
 
Weighted-average shares used to calculate earnings per share (in thousands)
Basic 499,239   501,453   500,186   500,887  
Diluted 501,653   502,445   502,480   501,610  
* Calculation not meaningful.
 
(a)   The condensed consolidated statements of income present the three and nine months ended September 27, 2015 and September 28, 2014. Subsidiaries operating outside the United States are included for the three and nine months ended August 23, 2015 and August 24, 2014.
 
(b) Exclusive of amortization of intangible assets, except as discussed in footnote (c) below.
 
(c)

Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as these intangible assets benefit multiple business functions. Amortization expense related to acquired intangible assets that are associated with a single function is included in Cost of sales, Selling, general and administrative expenses or Research and development expenses, as appropriate.

 
Certain amounts and percentages may reflect rounding adjustments.
 
 
     
ZOETIS INC.
RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS
(UNAUDITED)
(millions of dollars, except per share data)
 
Quarter ended September 27, 2015

GAAP Reported(a)

 

Purchase
Accounting
Adjustments

 

Acquisition-
Related
Costs(1)

 

Certain
Significant
Items(2)

 

Non-GAAP
Adjusted(b)

Revenue $ 1,214 $ $ $ $ 1,214
Cost of sales(c) 421 (2 ) (10 ) 409
Gross profit 793 2 10 805
Selling, general and administrative expenses(c) 374 (28 ) 346
Research and development expenses(c) 91 91
Amortization of intangible assets(d) 15 (11 ) 4
Restructuring charges and certain acquisition-related costs 13 (5 ) (8 )
Interest expense 29 29
Other (income)/deductions–net (2 ) (1 ) (3 )
Income before provision for taxes on income 273 13 6 46 338
Provision for taxes on income 83 4 (2 ) 85
Income from continuing operations 190 9 6 48 253
Net income attributable to noncontrolling interests 1 1
Net income attributable to Zoetis 189 9 6 48 252
Earnings per common share attributable to Zoetis–diluted(e) 0.38 0.02 0.01 0.09 0.50
 
Quarter ended September 28, 2014

GAAP Reported(a)

Purchase
Accounting
Adjustments

Acquisition-
Related
Costs(1)

Certain
Significant
Items(2)

Non-GAAP
Adjusted(b)

Revenue $ 1,210 $ $ $ $ 1,210
Cost of sales(c) 434 (2 ) (3 ) 429
Gross profit 776 2 3 781
Selling, general and administrative expenses(c) 394 1 (29 ) 366
Research and development expenses(c) 93 93
Amortization of intangible assets(d) 16 (12 ) 4
Restructuring charges and certain acquisition-related costs 2 (1 ) (1 )
Interest expense 29 29
Other (income)/deductions–net 4 (5 ) (1 )
Income before provision for taxes on income 238 13 1 38 290
Provision for taxes on income 71 4 1 6 82
Income from continuing operations 167 9 32 208
Net income attributable to noncontrolling interests 1 1
Net income attributable to Zoetis 166 9 32 207
Earnings per common share attributable to Zoetis–diluted(e) 0.33 0.02 0.06 0.41
 
                                   
     
ZOETIS INC.
RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS
(UNAUDITED)
(millions of dollars, except per share data)
 
Nine Months ended September 27, 2015

GAAP
Reported(a)

 

Purchase
Accounting
Adjustments

 

Acquisition-
Related
Costs(1)

 

Certain
Significant
Items(2)

 

Non-GAAP
Adjusted(b)

Revenue $ 3,491 $ $ $ $ 3,491
Cost of sales(c) 1,242 (7 ) (35 ) 1,200
Gross profit 2,249 7 35 2,291
Selling, general and administrative expenses(c) 1,107 (98 ) 1,009
Research and development expenses(c) 255 (1 ) 254
Amortization of intangible assets(d) 45 (33 ) 12
Restructuring charges and certain acquisition-related costs 280 (9 )

 

(271 )
Interest expense 86 86
Other (income)/deductions–net (2 ) (2 ) (4 )
Income before provision for taxes on income 476 41 11 406 934
Provision for taxes on income 157 14 (2 ) 88 257
Income from continuing operations 319 27 13 318 677
Net income attributable to noncontrolling interests 2 2
Net income attributable to Zoetis 317 27 13 318 675
Earnings per common share attributable to Zoetis–diluted(e) 0.63 0.05 0.03 0.63 1.34
 
Nine Months ended September 28, 2014

GAAP Reported (a)

Purchase
Accounting
Adjustments

Acquisition-
Related
Costs(1)

Certain
Significant
Items(2)

Non-GAAP
Adjusted(b)

Revenue $ 3,465 $ $ $ $ 3,465
Cost of sales(c) 1,226 (3 ) (14 ) 1,209
Gross profit 2,239 3 14 2,256
Selling, general and administrative expenses(c) 1,146 1 (90 ) 1,057
Research and development expenses(c) 272 (1 ) 271
Amortization of intangible assets(d) 46 (35 ) 11
Restructuring charges and certain acquisition-related costs 10 (5 ) (5 )
Interest expense 87 87
Other (income)/deductions–net 13 (18 ) (5 )
Income before provision for taxes on income 665 38 5 127 835
Provision for taxes on income 204 13 2 25 244
Income from continuing operations 461 25 3 102 591
Net income attributable to noncontrolling interests 4 4
Net income attributable to Zoetis 457 25 3 102 587
Earnings per common share attributable to Zoetis–diluted(e) 0.91 0.05 0.01 0.20 1.17
(a)   The condensed consolidated statements of income present the three and nine months ended September 27, 2015 and September 28, 2014. Subsidiaries operating outside the United States are included for the three and nine months ended August 30, 2015 and August 31, 2014.
 
(b) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.
 
(c) Exclusive of amortization of intangible assets, except as discussed in footnote (d) below.
 
(d)

Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as these intangible assets benefit multiple business functions. Amortization expense related to acquired intangible assets that are associated with a single function is included in Cost of sales, Selling, general and administrative expenses or Research and development expenses, as appropriate.

 
(e) EPS amounts may not add due to rounding.
 

See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2).

 
Certain amounts may reflect rounding adjustments.
 
 
 
ZOETIS INC.
NOTES TO RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS
(UNAUDITED)
(millions of dollars)
       

(1) Acquisition-related costs include the following:

 
Third Quarter Nine Months
2015     2014   2015     2014
Integration costs(a) $ 5   $ 1 $ 9 $ 5
Other(b) 1     2  
Total acquisition-related costs—pre-tax 6 1 11 5
Income taxes(c)   1   (2 ) 2
Total acquisition-related costs—net of tax $ 6   $   $ 13   $ 3
 
(a)  

Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and the integration of systems and processes. Included in Restructuring charges and certain acquisition-related costs.

 
(b)

Included in Other (income)/deductions—net.

 
(c)

Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate, as well as a tax charge related to the acquisition of certain assets of Abbott Animal Health.

 
Certain amounts may reflect rounding adjustments.
 
       

(2) Certain significant items include the following:

 
Third Quarter Nine Months
2015   2014 2015   2014
Operational efficiency initiative(a) $ 21 $ $ 294 $
Supply network strategy(b) 3 23
Other restructuring charges and cost-reduction/productivity initiatives(c) 1 5
Certain asset impairment charges(d) 6 2 6
Stand-up costs(e) 22 32 84 106
Net gain on sale of assets(f) (3 )
Other(g)   (1 ) 3   13  
Total certain significant items—pre-tax 46 38 406 127
Income taxes(h) (2 ) 6   88   25  
Total certain significant items—net of tax $ 48   $ 32   $ 318   $ 102  
(a)  

Includes restructuring charges of $8 million related to asset impairments for the three months ended September 27, 2015 and restructuring charges of $261 million related to employee termination costs ($228 million) and asset impairments ($33 million) for the nine months ended September 27, 2015, included in Restructuring charges and certain acquisition-related costs. Also includes inventory write-offs of $5 million for the three and nine months ended September 27, 2015, included in Cost of sales, and $8 million and $28 million primarily related to consulting fees for the three and nine months ended September 27, 2015, respectively, included in Selling, general and administrative expenses.

 
(b)

Includes restructuring charges of $10 million related to employee termination costs ($9 million) and asset impairments ($1 million) for the nine months ended September 27, 2015, included in Restructuring charges and certain acquisition-related costs. Also includes charges of $3 million and $13 million primarily related to consulting fees for the three and nine months ended September 27, 2015, respectively, included in Cost of sales.

 
(c)

Amounts related to our cost-reduction/productivity initiatives and were included in Restructuring charges and certain acquisition-related costs.

 
(d)

Included in Other (income)/deductions—net. For the nine months ended September 27, 2015, represents an impairment of IPR&D assets related to the termination of a canine oncology project. For the three and nine months ended September 28, 2014, represents an impairment charge related to an IPR&D project acquired with the FDAH acquisition in 2009.

 
(e)

Represents certain nonrecurring costs related to becoming an independent public company, such as new branding (including changes to the manufacturing process for required new packaging), the creation of standalone systems and infrastructure, site separation, and certain legal registration and patent assignment costs. Included in Cost of sales ($2 million and $16 million) and Selling, general and administrative expenses ($20 million and $68 million) for the three and nine months ended September 27, 2015, respectively. Included in Cost of sales ($3 million and $14 million) and Selling, general and administrative expenses ($29 million and $90 million), and Other (income)/deductions—net ($0 million and $2 million) for the three and nine months ended September 28, 2014, respectively.

 
(f)

For the nine months ended September 28, 2014, represents the Zoetis portion of a net gain on the sale of land by our Taiwan joint venture, included in Other (income)/deductions—net.

 
(g)

The nine months ended September 27, 2015, includes charges due to unusual investor-related activities in Selling, general and administrative expenses ($3 million). The nine months ended September 28, 2014, primarily includes a reserve associated with a commercial settlement in Mexico ($13 million), partially offset by the insurance recovery ($1 million income), and a pension plan settlement charge related to the divestiture of a manufacturing plant ($4 million), partially offset by an insurance recovery of litigation related charges ($2 million income), in Other (income)/deductions—net.

 
(h)

Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate. The nine months ended September 27, 2015 also includes a net tax benefit related to the revaluation of deferred taxes and other deferred tax adjustments.

 
Certain amounts may reflect rounding adjustments.
 
 
       
ZOETIS INC.

ADJUSTED SELECTED COSTS, EXPENSES AND INCOME (a)

(UNAUDITED)
(millions of dollars)
 
Third Quarter % Change
2015   2014 Total  

Foreign
Exchange

  Operational
Adjusted cost of sales $ 409 $ 429 (5 )% (12 )% 7 %
as a percent of revenue 33.7 % 35.5 % NA NA

NA

Adjusted SG&A expenses 346 366 (5 )% (8 )% 3 %
Adjusted R&D expenses 91 93 (2 )% (5 )% 3 %
Adjusted net income attributable to Zoetis 252 207 22 % (9 )% 31 %
 
 
Nine Months

% Change

2015 2014 Total

Foreign
Exchange

Operational
Adjusted cost of sales $ 1,200 $ 1,209 (1 )% (10 )% 9 %
as a percent of revenue 34.4 % 34.9 % NA NA NA
Adjusted SG&A expenses 1,009 1,057 (5 )% (8 )% 3 %
Adjusted R&D expenses 254 271 (6 )% (3 )% (3 )%
Adjusted net income attributable to Zoetis 675 587 15 % (7 )% 22 %
(a)   Adjusted cost of sales, adjusted selling, general, and administrative (SG&A) expenses, adjusted research and development (R&D) expenses, and adjusted net income attributable to Zoetis are defined as the corresponding reported U.S. generally accepted accounting principles (GAAP) income statement line items excluding purchase accounting adjustments, acquisition-related costs, and certain significant items. Reconciliations of certain reported to adjusted information for the three and nine months ended September 27, 2015 and September 28, 2014 are provided in the materials accompanying this report. These adjusted income statement line item measures are not, and should not be viewed as, substitutes for the corresponding U.S. GAAP line items.
 
     
     
ZOETIS INC.
2015 GUIDANCE
 
         
Selected Line Items

(millions of dollars, except per share amounts)

      Full Year 2015
Revenue       $4,700 to $4,750
Operational growth       6.5% to 7.5%
Adjusted cost of sales as a percentage of revenue(a)       Approximately 35%
Adjusted SG&A expenses(a)       $1,375 to $1,405
Adjusted R&D expenses(a)       $350 to $370
Adjusted interest expense and other (income)/deductions(a)       Approximately $110
Adjusted EBIT margin(a)       Approximately 28%
Effective tax rate on adjusted income(a)       Approximately 28%
Adjusted diluted EPS(a)       $1.70 to $1.74
Adjusted net income(a)       $855 to $875
Operational growth       16% to 19%
Certain significant items(b) and acquisition-related costs       $470 to $490
Reported diluted EPS       $0.82 to $0.89
 

A reconciliation of 2015 adjusted net income and adjusted diluted EPS guidance to 2015 reported net income attributable to Zoetis and reported diluted EPS attributable to Zoetis common shareholders guidance follows:

         
      Full-Year 2015 Guidance
(millions of dollars, except per share amounts) Net Income   Diluted EPS
Adjusted net income/diluted EPS(a) guidance ~$855 - $875 ~$1.70 - $1.74
Purchase accounting adjustments ~(40) ~(0.08)
Certain significant items(b) and acquisition-related costs   ~(385 - 400)   ~(0.77 - 0.80)
Reported net income attributable to Zoetis/diluted EPS guidance   ~$415 - $450   ~$0.82 - $0.89
(a)   Adjusted net income and its components and adjusted diluted EPS are defined as reported U.S. generally accepted accounting principles (GAAP) net income and its components and reported diluted EPS excluding purchase accounting adjustments, acquisition-related costs and certain significant items. Adjusted cost of sales, adjusted selling, general and administrative (SG&A) expenses, adjusted research and development (R&D) expenses, adjusted interest expense and adjusted other (income)/deductions are income statement line items prepared on the same basis, and, therefore, components of the overall adjusted income measure. Adjusted earnings before interest and taxes (EBIT) is defined as reported EBIT excluding purchase accounting adjustments, acquisition-related costs and certain significant items. Despite the importance of these measures to management in goal setting and performance measurement, adjusted net income and its components and adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, adjusted net income and its components and adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Adjusted net income and its components and adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance. Adjusted net income and its components and adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS.
 
(b) Primarily includes certain nonrecurring costs related to restructuring and other charges for the operational efficiency initiative and supply network strategy, becoming an independent public company, such as new branding (including changes to the manufacturing process for required new packaging), the creation of standalone systems and infrastructure, site separation, and certain legal registration and patent assignment costs.
 
     
       
ZOETIS INC.
2016 - 2017 GUIDANCE
 
             
Selected Line Items

(millions of dollars, except per share amounts)

      2016   2017
Revenue       $4,750 to $4,875   $5,025 to $5,225
Operational growth       3% to 5%   4% to 9%
Adjusted cost of sales as a percentage of revenue(a)       33% to 34%   32% to 33%
Adjusted SG&A expenses(a)       $1,310 to $1,360   $1,270 to $1,360
Adjusted R&D expenses(a)       $360 to $380   $360 to $380
Adjusted interest expense and other (income)/deductions(a)       Approximately $150   Approximately $150
Adjusted EBIT margin(a)       Approximately 31%   Approximately 34%
Effective tax rate on adjusted income(a)       Approximately 28%   Approximately 28%
Adjusted diluted EPS(a)       $1.84 to $1.94   $2.24 to $2.38
Adjusted net income(a)       $925 to $975   $1,125 to $1,195
Operational growth       14% to 20%   18% to 26%
Certain significant items(b) and acquisition-related costs       $130 to $180   $50 to $80
Reported diluted EPS(c)       $1.50 to $1.68   $2.04 to $2.22
 

A reconciliation of 2016 and 2017 adjusted net income and adjusted diluted EPS guidance to 2016 and 2017 reported net income attributable to Zoetis and reported diluted EPS attributable to Zoetis common shareholders guidance follows:

         
      Full-Year 2016 Guidance
(millions of dollars, except per share amounts) Net Income   Diluted EPS
Adjusted net income/diluted EPS(a) guidance ~$925 - $975 ~$1.84 - $1.94
Purchase accounting adjustments ~(45) ~(0.09)
Certain significant items(b) and acquisition-related costs       ~(85 - 125)   ~(0.17 - 0.25)
Reported net income attributable to Zoetis/diluted EPS guidance(c)       ~$755 - $845   ~$1.50 - $1.68
 
         
Full-Year 2017 Guidance
(millions of dollars, except per share amounts) Net Income Diluted EPS
Adjusted net income/diluted EPS(a) guidance

~$1,125 - $1,195

~$2.24 - $2.38
Purchase accounting adjustments ~(45) ~(0.09)
Certain significant items(b) and acquisition-related costs       ~(35 - 55)   ~(0.07 - 0.11)
Reported net income attributable to Zoetis/diluted EPS guidance(c)       ~$1,025 - $1,115   ~$2.04 - $2.22
(a)   Adjusted net income and its components and adjusted diluted EPS are defined as reported U.S. generally accepted accounting principles (GAAP) net income and its components and reported diluted EPS excluding purchase accounting adjustments, acquisition-related costs and certain significant items. Adjusted cost of sales, adjusted selling, general and administrative (SG&A) expenses, adjusted research and development (R&D) expenses, adjusted interest expense, adjusted other (income)/deductions are income statement line items prepared on the same basis, and, therefore, components of the overall adjusted income measure. Adjusted earnings before interest and taxes (EBIT) is defined as reported EBIT excluding purchase accounting adjustments, acquisition-related costs and certain significant items. Despite the importance of these measures to management in goal setting and performance measurement, adjusted net income and its components and adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, adjusted net income and its components and adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Adjusted net income and its components and adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance. Adjusted net income and its components and adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS.
 
(b) Primarily includes certain nonrecurring costs related to restructuring and other charges for the operational efficiency initiative and supply network strategy, becoming an independent public company, such as new branding (including changes to the manufacturing process for required new packaging), the creation of standalone systems and infrastructure, site separation, and certain legal registration and patent assignment costs.
 
(c) Includes preliminary estimate of purchase price allocation for PHARMAQ.
 
     
       
ZOETIS INC.

CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES

(UNAUDITED)
(millions of dollars)
 
Third Quarter % Change
2015   2014 Total   Foreign Exchange   Operational
Revenue:
Livestock $ 750 $ 790 (5 )% (10 )% 5 %
Companion Animal 451 408 11 % (7 )% 18 %
Contract Manufacturing 13   12   8 % (5 )% 13 %
Total Revenue $ 1,214   $ 1,210  

%

(9 )% 9 %
 
 
 
U.S.
Livestock $ 348 $ 308 13 % % 13 %
Companion Animal 284   224   27 % % 27 %
Total U.S. Revenue $ 632   $ 532   19 % % 19 %
 
International
Livestock $ 402 $ 482 (17 )% (17 )% %
Companion Animal 167   184   (9 )% (16 )% 7 %
Total International Revenue $ 569   $ 666   (15 )% (17 )% 2 %
 
 
 
Livestock:
Cattle $ 432 $ 437 (1 )% (9 )% 8 %
Swine 163 179 (9 )% (10 )% 1 %
Poultry 132 147 (10 )% (10 )% %
Other 23   27   (15 )% (15 )% %
Total Livestock Revenue $ 750   $ 790   (5 )% (10 )% 5 %
 
Companion Animal:
Horses $ 35 $ 38 (8 )% (10 )% 2 %
Dogs and Cats 416   370   12 % (8 )% 20 %
Total Companion Animal Revenue $ 451   $ 408   11 % (7 )% 18 %
(a)   Beginning in the second quarter of 2015, we changed our segment reporting structure. The prior period presentation has been revised to reflect the new segment reporting structure.
 
Certain amounts and percentages may reflect rounding adjustments.
 
 
       
ZOETIS INC.

CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES

(UNAUDITED)
(millions of dollars)
 
Nine Months % Change
2015   2014 Total   Foreign Exchange   Operational
Revenue:
Livestock $ 2,155 $ 2,199 (2 )% (9 )% 7 %
Companion Animal 1,299 1,227 6 % (6 )% 12 %
Contract Manufacturing 37   39   (5 )% (7 )% 2 %
Total Revenue $ 3,491   $ 3,465   1 % (8 )% 9 %
 
 
 
U.S.
Livestock $ 903 $ 795 14 % % 14 %
Companion Animal 789   675   17 % % 17 %
Total U.S. Revenue $ 1,692   $ 1,470   15 % % 15 %
 
International
Livestock $ 1,252 $ 1,404 (11 )% (14 )% 3 %
Companion Animal 510   552   (8 )% (15 )% 7 %
Total International Revenue $ 1,762   $ 1,956   (10 )% (14 )% 4 %
 
 
 
Livestock:
Cattle $ 1,201 $ 1,207 % (8 )% 8 %
Swine 495 496 % (9 )% 9 %
Poultry 399 428 (7 )% (8 )% 1 %
Other 60   68   (12 )% (15 )% 3 %
Total Livestock Revenue $ 2,155   $ 2,199   (2 )% (9 )% 7 %
 
Companion Animal:
Horses $ 117 $ 127 (8 )% (7 )% (1 )%
Dogs and Cats 1,182   1,100   7 % (7 )% 14 %
Total Companion Animal Revenue $ 1,299   $ 1,227   6 % (6 )% 12 %
(a)   Beginning in the second quarter of 2015, we changed our segment reporting structure. The prior period presentation has been revised to reflect the new segment reporting structure.
 
Certain amounts and percentages may reflect rounding adjustments.
 
 
       
ZOETIS INC.
CONSOLIDATED REVENUE BY KEY INTERNATIONAL MARKETS
(UNAUDITED)
(millions of dollars)
 
Third Quarter % Change
2015     2014   Total  

Foreign
Exchange

  Operational
Total International       $ 569     $ 666     (15 )% (17 )%   2 %
Australia 40   47 (15 )% (20 )% 5 %
Brazil 54 71 (24 )% (36 )% 12 %
Canada 35 39 (10 )% (15 )% 5 %
China 30 24 25 % 1 % 24 %
France 24 40 (40 )% (13 )% (27 )%
Germany 27 34 (21 )% (19 )% (2 )%
Italy 21 26 (19 )% (17 )% (2 )%
Japan 23 17 35 % (21 )% 56 %
Mexico 19 20 (5 )% (16 )% 11 %
Spain 21 23 (9 )% (19 )% 10 %
United Kingdom 43 42 2 % (10 )% 12 %
Other Developed 68 84 (19 )% (17 )% (2 )%
Other Emerging 164 199 (18 )% (12 )% (6 )%
 
Nine Months % Change
2015   2014   Total

Foreign
Exchange

Operational
Total International       $ 1,762     $ 1,956     (10 )% (14 )%   4 %
Australia 109 125 (13 )% (16 )% 3 %
Brazil 185 218 (15 )% (27 )% 12 %
Canada 117 130 (10 )% (12 )% 2 %
China 94 80 18 % % 18 %
France 77 114 (32 )% (14 )% (18 )%
Germany 86 107 (20 )% (17 )% (3 )%
Italy 66 77 (14 )% (17 )% 3 %
Japan 75 78 (4 )% (14 )% 10 %
Mexico 55 62 (11 )% (14 )% 3 %
Spain 60 67 (10 )% (18 )% 8 %
United Kingdom 122 121 1 % (9 )% 10 %
Other Developed 211 242 (13 )% (14 )% 1 %
Other Emerging 505 535 (6 )% (11 )% 5 %
Certain amounts and percentages may reflect rounding adjustments.
 
 
       
ZOETIS INC.

SEGMENT(a) EARNINGS

(UNAUDITED)
(millions of dollars)
 
Third Quarter % Change
2015   2014 Total  

Foreign
Exchange

  Operational

U.S.:

Revenue $ 632 $ 532 19 %

%

19 %
Cost of Sales 147   126   17 % % 17 %
Gross Profit 485 406 19 % % 19 %
Gross Margin 76.7 % 76.3 %
Operating Expenses 100 93 8 % % 8 %
Other (income)/deductions (1 )   * % *
U.S. Earnings $ 386 $ 313 23 % % 23 %
 

International:

Revenue $ 569 $ 666 (15 )% (17 )% 2 %
Cost of Sales 209   241   (13 )% (13 )% %
Gross Profit 360 425 (15 )% (18 )% 3 %
Gross Margin 63.3 % 63.8 %
Operating Expenses 137 168 (18 )% (16 )% (2 )%
Other (income)/deductions 4   2   100 % * *
International Earnings $ 219 $ 255 (14 )% (21 )% 7 %
 
Total Reportable Segments $ 605 $ 568 7 % (9 )% 16 %
 
Other business activities(b) (73 ) (76 ) (4 )%
Reconciling Items:
Corporate(c) (138 ) (142 ) (3 )%
Purchase accounting adjustments(d) (13 ) (13 ) %
Acquisition-related costs(e) (6 ) (1 ) *
Certain significant items(f) (46 ) (38 ) 21 %
Other unallocated(g) (56 ) (60 ) (7 )%
Total Earnings(h) $ 273   $ 238   15 %
* Calculation not meaningful.
 
(a)   Beginning in the second quarter of 2015, we changed our segment reporting structure and recategorized certain costs that are not allocated to our operating segments. The prior period presentation has been revised to reflect the new segment reporting structure.
 
(b) Other business activities reflect the research and development costs managed by our Research and Development organization as well as our contract manufacturing business.
 
(c) Corporate includes, among other things, administration expenses, interest expense, certain compensation and other costs not charged to our operating segments.
 
(d) Purchase accounting adjustments include certain charges related to intangible assets and property, plant and equipment not charged to our operating segments.
 
(e) Acquisition-related costs can include costs associated with acquiring, integrating and restructuring newly acquired businesses, such as transaction costs, integration costs, restructuring charges and additional depreciation associated with asset restructuring.
 
(f) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain costs related to becoming an independent public company, restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition, costs associated with the operational efficiency initiative, certain legal and commercial settlements, and the impact of divestiture-related gains and losses.
 
(g) Includes overhead expenses associated with our manufacturing and supply operations not directly attributable to an operating segment, as well as procurement costs.
 
(h) Defined as income before provision for taxes on income.
 
Certain amounts and percentages may reflect rounding adjustments.
 
 
       
ZOETIS INC.

SEGMENT(a) EARNINGS

(UNAUDITED)
(millions of dollars)
 
Nine Months % Change
2015   2014 Total   Foreign Exchange   Operational

U.S.:

Revenue $ 1,692 $ 1,470 15 % % 15 %
Cost of Sales 399   343   16 % % 16 %
Gross Profit 1,293 1,127 15 % % 15 %
Gross Margin 76.4 % 76.7 %
Operating Expenses 274 278 (1 )% % (1 )%
Other (income)/deductions (1 )   * % *
U.S. Earnings $ 1,020 $ 849 20 % % 20 %
 

International:

Revenue $ 1,762 $ 1,956 (10 )% (14 )% 4 %
Cost of Sales 638   701   (9 )% (11 )% 2 %
Gross Profit 1,124 1,255 (10 )% (15 )% 5 %
Gross Margin 63.8 % 64.2 %
Operating Expenses 423 490 (14 )% (14 )% %
Other (income)/deductions 10   5   100 % 60 % 40 %
International Earnings $ 691 $ 760 (9 )% (17 )% 8 %
 
Total Reportable Segments $ 1,711 $ 1,609 6 % (8 )% 14 %
 
Other business activities(b) (208 ) (224 ) (7 )%
Reconciling Items:
Corporate(c) (392 ) (389 ) 1 %
Purchase accounting adjustments(d) (41 ) (38 ) 8 %
Acquisition-related costs(e) (11 ) (5 ) *
Certain significant items(f) (406 ) (127 ) *
Other unallocated(g) (177 ) (161 ) 10 %
Total Earnings(h) $ 476   $ 665   (28 )%
* Calculation not meaningful.
 
(a)   Beginning in the second quarter of 2015, we changed our segment reporting structure and recategorized certain costs that are not allocated to our operating segments. The prior period presentation has been revised to reflect the new segment reporting structure.
 
(b) Other business activities reflect the research and development costs managed by our Research and Development organization as well as our contract manufacturing business.
 
(c) Corporate includes, among other things, administration expenses, interest expense, certain compensation and other costs not charged to our operating segments.
 
(d) Purchase accounting adjustments include certain charges related to intangible assets and property, plant and equipment not charged to our operating segments.
 
(e) Acquisition-related costs can include costs associated with acquiring, integrating and restructuring newly acquired businesses, such as transaction costs, integration costs, restructuring charges and additional depreciation associated with asset restructuring.
 
(f) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain costs related to becoming an independent public company, restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition, costs associated with the operational efficiency initiative, certain legal and commercial settlements, and the impact of divestiture-related gains and losses.
 
(g) Includes overhead expenses associated with our manufacturing and supply operations not directly attributable to an operating segment, as well as procurement costs.
 
(h) Defined as income before provision for taxes on income.
 
Certain amounts and percentages may reflect rounding adjustments.

Contact:

Media:
Bill Price, 1-973-443-2742 (o)
william.price@zoetis.com
or
Elinore White, 1-973-443-2835 (o)
elinore.y.white@zoetis.com
or
Investor:
John O'Connor, 1-973-822-7088 (o)
john.oconnor@zoetis.com
or
Steve Frank, 1-973-822-7141 (o)
steve.frank@zoetis.com